Received Jun 2, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | KR94A | — |
Arexvy adjuvant only administration; Arexvy adjuvant only administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate preparation of medication in a male patient who received RSVPreF3 adjuvanted (Arexvy) suspension for injection (batch number KR94A with expiry date 23-JAN-2027) for prophylaxis. On 15-MAY-2026, the patient received Arexvy. On 15-MAY-2026, an unknown time after receiving Arexvy, the patient experienced inappropriate preparation of medication (Verbatim: Arexvy adjuvant only administration) and inappropriate dose of vaccine administered (Verbatim: Arexvy adjuvant only administration). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 29-MAY-2026 Pharmacist wanted to know how to proceed. The vaccine administration facility was the same as primary reporter.